Bicara Therapeutics Inc. (BCAX)
(Delayed Data from NSDQ)
$10.20 USD
0.00 (0.00%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $10.16 -0.04 (-0.39%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BCAX 10.20 0.00(0.00%)
Will BCAX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BCAX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for BCAX
Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board | BCAX Stock News
FMR LLC's Strategic Acquisition of Bicara Therapeutics Inc Shares
FMR LLC Reduces Stake in Bicara Therapeutics Inc: A Strategic Portfolio Adjustment
Bicara Therapeutics Elects New Directors at Annual Meeting
Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus